156 related articles for article (PubMed ID: 22692351)
1. Quality control of involved-field radiotherapy for patients with early stage Hodgkin's lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group.
Kriz J; Bangard C; Haverkamp U; Bongartz R; Baues C; Engert A; Mueller RP; Eich HT
Strahlenther Onkol; 2012 Aug; 188(8):660-5. PubMed ID: 22692351
[TBL] [Abstract][Full Text] [Related]
2. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
3. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
Müller RP; Eich HT
Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
[TBL] [Abstract][Full Text] [Related]
4. [New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology].
Eich HT; Müller RP; Ansén S; Josting A; Engert A; Hansemann K; Pfistner B; Wolf J; Willich N; Diehl V
Rontgenpraxis; 2003; 55(3):114-24. PubMed ID: 15119314
[TBL] [Abstract][Full Text] [Related]
5. Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma: an analysis of the German Hodgkin Study Group.
Eich HT; Engenhart-Cabillic R; Hansemann K; Lukas P; Schneeweiss A; Seegenschmiedt H; Skripnitchenko R; Staar S; Willich N; Müller RP
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1419-24. PubMed ID: 18234433
[TBL] [Abstract][Full Text] [Related]
6. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
[TBL] [Abstract][Full Text] [Related]
8. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG).
Eich HT; Müller RP; Engenhart-Cabillic R; Lukas P; Schmidberger H; Staar S; Willich N;
Strahlenther Onkol; 2008 Aug; 184(8):406-10. PubMed ID: 18956517
[TBL] [Abstract][Full Text] [Related]
9. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
Eich HT; Gossmann A; Engert A; Kriz J; Bredenfeld H; Hansemann K; Skripnitchenko R; Brillant C; Pfistner B; Staar S; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1187-92. PubMed ID: 17703895
[TBL] [Abstract][Full Text] [Related]
10. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
Hoppe BS; Flampouri S; Zaiden R; Slayton W; Sandler E; Ozdemir S; Dang NH; Lynch JW; Li Z; Morris CG; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1053-1059. PubMed ID: 24928256
[TBL] [Abstract][Full Text] [Related]
11. Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).
Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfart K; Lukas P; Plütschow A; Schmidberger H; Staar S; Fuchs M; Engert A; Eich HT
Strahlenther Onkol; 2017 Feb; 193(2):109-115. PubMed ID: 27596217
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Advani RH; Hong F; Fisher RI; Bartlett NL; Robinson KS; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Gordon LI; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ
J Clin Oncol; 2015 Jun; 33(17):1936-42. PubMed ID: 25897153
[TBL] [Abstract][Full Text] [Related]
14. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations.
Fiandra C; Filippi AR; Catuzzo P; Botticella A; Ciammella P; Franco P; Borca VC; Ragona R; Tofani S; Ricardi U
Radiat Oncol; 2012 Nov; 7():186. PubMed ID: 23122028
[TBL] [Abstract][Full Text] [Related]
15. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
[TBL] [Abstract][Full Text] [Related]
16. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.
Kreissl S; Mueller H; Goergen H; Mayer A; Brillant C; Behringer K; Halbsguth TV; Hitz F; Soekler M; Shonukan O; Rueffer JU; Flechtner HH; Fuchs M; Diehl V; Engert A; Borchmann P;
Lancet Oncol; 2016 Oct; 17(10):1453-1462. PubMed ID: 27612583
[TBL] [Abstract][Full Text] [Related]
17. Large mediastinal tumor mass as a prognostic factor in Hodgkin's lymphoma. Is the definition on the basis of a chest radiograph in the era of CT obsolete?
Kriz J; Mueller RP; Mueller H; Kuhnert G; Engert A; Kobe C; Haverkamp U; Eich HT
Strahlenther Onkol; 2012 Nov; 188(11):1020-4. PubMed ID: 23053141
[TBL] [Abstract][Full Text] [Related]
18. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90.
Dieckmann K; Pötter R; Wagner W; Prott FJ; Hörnig-Franz I; Rath B; Schellong G
Radiother Oncol; 2002 Feb; 62(2):191-200. PubMed ID: 11937246
[TBL] [Abstract][Full Text] [Related]
19. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
